Lifecare AS
LIFE.OL
Oslo Stock Exchange0.29
NOK
+0.00
- -
Lifecare AS
LIFE.OL
(Oslo Stock Exchange)
Recent
price
0.29
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lifecare ASA is a clinical-stage medical sensor company specializing in the development and commercialization of implantable nanobiosensor technology for continuous glucose monitoring (CGM) in humans and veterinary applications. The company’s core products include the Sencell sensor, a miniaturized implantable device that utilizes osmotic pressure and nanotechnology to provide long-term, calibration-free glucose monitoring with high accuracy and user convenience. Lifecare also develops related medical devices such as nanostrain biosensors capable of measuring various physiological parameters, and devices for subdermal implant removal. The company targets the diabetes management market across Europe and North America, focusing on both human and veterinary segments. Founded in 2006 and headquartered in Bergen, Norway, Lifecare operates with a research-intensive approach emphasizing product innovation and clinical validation. In the past two years, Lifecare has achieved key milestones including the finalization of product design and production setup for near-term veterinary market entry, securing NOK 80 million in funding to support development and regulatory progress, and advancement into the final regulatory review phase for first-in-human clinical approval anticipated in early 2026. The company reported positive early results from longevity trials in dogs demonstrating excellent biocompatibility, safety, and reliable glucose data transmission, leading to improvements in material stability and firmware. Lifecare is preparing for a commercial launch in Europe by 2027 with a partner-driven, scalable B2B model. It has also automated sensor production processes at its Reutlingen laboratory to scale manufacturing. Strategic priorities include expanding clinical trials, strengthening organizational capabilities, and advancing CE-marking efforts to enable commercialization. Lifecare’s pipeline and focused capital strategy position it to capture significant market share in next-generation continuous glucose monitoring solutions for diabetes care.